Document is current

Article History

Received: 9 August 2019

Accepted: 26 September 2019

First Online: 9 October 2019

Ethics approval and consent to participate

: Since previous Ethics Committee approval was obtained for each study and no subject identifying information was disclosed, ethical approval was not required for this analysis of data. The studies were conducted in compliance with the declaration of Helsinki and its revisions, and with the ICH Guidelines on Medicinal products. All participants were previously informed and provided written informed consent.

: Not applicable.

: JM has been member of national and international scientific advisory boards (consulting), received fees for lectures, and grants for research projects from Allakos, ALK-Abelló, Genentech-Roche, Glenmark, GSK, Hartington Pharmaceuticals, Menarini, MSD, Mylan-MEDA Pharma, Novartis, Sanofi-Genzyme-Regeneron, UCB, and Uriach Group. II is an employee of J Uriach y Compañía, S.A. KO received lecture fees from Tanabe Mitsubishi Co, Taiho Pharma, Meiji Pharma, and Torii Pharma. GWC reports having received in the last 3 years research grants as well as lecture or advisory board fees from: Menarini, ALK-Abelló, Allergy Therapeutics, AstraZeneca-Medimmune, Boehringer Ingelheim, Chiesi, Danone, Guidotti-Malesci, GSK, Hal Allergy, MSD, Mundipharma, Novartis, Orion, Sanofi-Genzyme-Regeneron, Stallergenes, Uriach group, and Valeas. JB reports personal fees from Chiesi, Cipla, Hikma, Menarini, Mundipharma, Mylan, Novartis, Purina, Sanofi-Aventis, Takeda, Teva, Uriach group, other from KYomed-Innov. AV has previously received honoraria for speaking at sponsored meetings from Uriach group, GSK, AstraZeneca, Chiesi and Novartis, and is a consultant and grants for research for AstraZeneca, Menarini, Uriach group, Novartis, Mylan-MEDA Pharma and Sanofi.